New hope for kidney patients: targeted drug may replace harsh chemotherapy
NCT ID NCT06781944
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares a newer targeted drug, obinutuzumab, against a standard treatment (cyclophosphamide plus steroids) for primary membranous nephropathy, a kidney disease that can lead to kidney failure. About 144 adults with moderate to severe protein in their urine will receive either obinutuzumab infusions or the standard regimen. The goal is to see if obinutuzumab can achieve better remission rates with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Obinutuzumab
What this could lead to
If successful, obinutuzumab could offer a more effective and less toxic treatment option for people with primary membranous nephropathy, potentially reducing the need for harsh chemotherapy-like drugs.
What could go wrong
This is a Phase 3 trial, but it is still early to know if obinutuzumab is truly better or safer than the current standard. The study is open-label, which can introduce bias, and long-term outcomes are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••